Two COVID-19 vaccine candidates have proven safe for humans and produced strong immune reactions among patients involved in two separate clinical trials, doctors said yesterday.
The first trial among more than a thousand adults in Britain found that the vaccine induced “strong antibody and T-cell immune responses” against the novel coronavirus.
A separate trial in China involving more than 500 people showed most had developed widespread antibody immune response.
The studies, published in The Lancet medical journal, constitute a major step on the road towards a COVID-19 vaccine that is effective and safe for widespread use.
The authors of the studies said they encountered few adverse side effects from the vaccine candidates.
They did, however, caution that more research was needed, particularly among older adults who are disproportionately at risk of dying from COVID-19.
Co-author Sarah Gilbert from the University of Oxford said the results “hold promise”.
“If our vaccine is effective it is a promising option, as these types of vaccines can be manufactured at large scale.”
The pandemic has seen an unprecedented mobilisation of funding and research to rush through a vaccine that can protect billions of people worldwide.
More than 20 candidate vaccines are currently being tested on humans.
Both studies were phase 2 trials, which test whether the vaccine provokes an immune response and can be well tolerated by patients.
For its trial, the team at Oxford used a genetically modified strain of the common cold virus that infects chimpanzees.
They manipulated the virus to train cells to recognise the viral spike protein, which helps teach the immune system to recognise COVID-19.
As well as developing antibodies in their blood, patients given the vaccine were found to have developed a robust T-cell response — helping their body identify and neutralise the virus.
“The immune system has two ways of finding and attacking pathogens — antibody and T-cell responses,” said Andrew Pollard, a member of the Oxford team.
“This vaccine is intended to induce both, so it can attack the virus when it’s circulating in the body, as well as attacking infected cells.”
The Oxford team found that among the 500 or so patients given a single dose of the vaccine — developed jointly with pharmaceutical giant AstraZeneca — their immune response peaked around day 14 and decreased slightly by day 56, the end of the study period.
The other 500 patients were instead given a meningitis vaccine as a placebo.
The second trial, led by China’s Jiangsu Provincial Center for Disease Control and Prevention, used a weakened human cold virus modified to deliver genetic material that teaches cells to recognise the novel coronavirus.
Two groups of patients were given either a high or low dose of the vaccine.
More than 90 per cent of people in both groups showed either antibody or T-cell immune responses between 14 and 28 days post-vaccine.